iTeos Therapeutics Management
Management criteria checks 3/4
iTeos Therapeutics' CEO is Michel Detheux, appointed in Aug 2011, has a tenure of 13.33 years. total yearly compensation is $5.77M, comprised of 10% salary and 90% bonuses, including company stock and options. directly owns 0.058% of the company’s shares, worth $158.83K. The average tenure of the management team and the board of directors is 4.5 years and 4.5 years respectively.
Key information
Michel Detheux
Chief executive officer
US$5.8m
Total compensation
| CEO salary percentage | 10.0% |
| CEO tenure | 13.3yrs |
| CEO ownership | 0.06% |
| Management average tenure | 4.5yrs |
| Board average tenure | 4.5yrs |
Recent management updates
Recent updates
iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024
Dec 18iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Nov 15
iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT
Sep 15Is iTeos Therapeutics (NASDAQ:ITOS) In A Good Position To Deliver On Growth Plans?
Aug 11iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism
Jul 09iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 25iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
Jan 10Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%
May 13Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding
Mar 21The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically
Aug 12iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04
Aug 10iTeos Therapeutics: Too Many Unknowns
Jul 27News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts
May 11Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic
Nov 25We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth
Aug 24iTeos Therapeutics: My Calculations Suggest Q3 Earnings Will Exceed $10 Per Share
Aug 15GlaxoSmithKline - iTeos deal intensifies competition in anti-TIGIT space: Piper Sandler
Jun 15We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth
Feb 07Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions?
Dec 16
iTeos Therapeutics EPS misses by $0.11
Nov 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$121m |
| Jun 30 2024 | n/a | n/a | -US$108m |
| Mar 31 2024 | n/a | n/a | -US$135m |
| Dec 31 2023 | US$6m | US$579k | -US$113m |
| Sep 30 2023 | n/a | n/a | -US$62m |
| Jun 30 2023 | n/a | n/a | -US$28m |
| Mar 31 2023 | n/a | n/a | US$12m |
| Dec 31 2022 | US$11m | US$556k | US$97m |
| Sep 30 2022 | n/a | n/a | US$261m |
| Jun 30 2022 | n/a | n/a | US$330m |
| Mar 31 2022 | n/a | n/a | US$298m |
| Dec 31 2021 | US$6m | US$525k | US$215m |
| Sep 30 2021 | n/a | n/a | US$15m |
| Jun 30 2021 | n/a | n/a | -US$67m |
| Mar 31 2021 | n/a | n/a | -US$50m |
| Dec 31 2020 | US$17m | US$463k | -US$43m |
| Sep 30 2020 | n/a | n/a | -US$35m |
| Jun 30 2020 | n/a | n/a | -US$31m |
| Mar 31 2020 | n/a | n/a | -US$28m |
| Dec 31 2019 | US$2m | US$460k | -US$27m |
Compensation vs Market: Michel's total compensation ($USD5.77M) is above average for companies of similar size in the US market ($USD1.38M).
Compensation vs Earnings: Michel's compensation has been consistent with company performance over the past year.
CEO
Michel Detheux (57 yo)
13.3yrs
Tenure
US$5,767,774
Compensation
Dr. Michel Detheux, Ph D, is Chairman of the Board at InnoSkel. He serves as an Independent Chairman at Ona Therapeutics, S.L. since December 2021.He has served as the Chief Executive Officer and Director...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 13.3yrs | US$5.77m | 0.058% $ 158.8k | |
| Chief Financial Officer | 4.5yrs | US$2.72m | 0.067% $ 182.5k | |
| Chief Operating Officer | 5.3yrs | US$2.80m | 0.26% $ 701.4k | |
| Chief Scientific Officer | 2.9yrs | no data | no data | |
| Executive Vice President of Legal | 1.9yrs | no data | no data | |
| Executive Vice President of Human Resources | 4.9yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
4.5yrs
Average Tenure
50.5yo
Average Age
Experienced Management: ITOS's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 12.9yrs | US$5.77m | 0.058% $ 158.8k | |
| Independent Director | 4.5yrs | US$317.52k | 0% $ 0 | |
| Independent Chairman of the Board | 6.5yrs | US$416.42k | 0% $ 0 | |
| Independent Director | 6.5yrs | US$303.52k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.7yrs | US$305.02k | 0% $ 0 | |
| Independent Director | 3.7yrs | US$308.27k | 0% $ 0 | |
| Independent Director | less than a year | US$323.44k | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
4.5yrs
Average Tenure
57yo
Average Age
Experienced Board: ITOS's board of directors are considered experienced (4.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 03:44 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
iTeos Therapeutics, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ulz | Baird |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Lut Ming Cheng | J.P. Morgan |